Rational design of shepherdin, a novel anticancer agent.

[1]  D. Altieri,et al.  Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. , 2004, The Journal of clinical investigation.

[2]  Tak W. Mak,et al.  Pathways of apoptotic and non-apoptotic death in tumour cells , 2004, Nature Reviews Cancer.

[3]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[4]  L. Neckers,et al.  Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin. , 2004, Chemistry & biology.

[5]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[6]  H. Beere.  `The stress of dying': the role of heat shock proteins in the regulation of apoptosis , 2004, Journal of Cell Science.

[7]  H. Saragovi,et al.  Novel approaches for targeted cancer therapy. , 2004, Current cancer drug targets.

[8]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[9]  L. Pearl,et al.  The Mechanism of Hsp90 Regulation by the Protein Kinase-Specific Cochaperone p50cdc37 , 2004, Cell.

[10]  D. Altieri,et al.  Full-length dominant-negative survivin for cancer immunotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  W. Sessa,et al.  Regulation of survivin function by Hsp90 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Neckers,et al.  Heat shock protein 90 , 2003, Current opinion in oncology.

[13]  P. Kabouridis.  Biological applications of protein transduction technology. , 2003, Trends in biotechnology.

[14]  E. Sausville,et al.  Clinical development of 17-allylamino, 17-demethoxygeldanamycin. , 2003, Current cancer drug targets.

[15]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[16]  O. Sieber,et al.  Genomic instability — the engine of tumorigenesis? , 2003, Nature Reviews Cancer.

[17]  M. Sawada,et al.  Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70 , 2003, Nature Cell Biology.

[18]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[19]  Chrisostomos Prodromou,et al.  Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. , 2003, Molecular cell.

[20]  N. Rosen,et al.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 , 2002, Oncogene.

[21]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[22]  Jason C. Young,et al.  Hsp90: a specialized but essential protein-folding tool. , 2001, The Journal of cell biology.

[23]  S. Parodi,et al.  A retro‐inverso peptide homologous to helix 1 of c‐Myc is a potent and specific inhibitor of proliferation in different cellular systems , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  B. Druker,et al.  STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. , 2000, The Lancet. Oncology.

[25]  L. Neckers,et al.  The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone* , 2000, The Journal of Biological Chemistry.

[26]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[27]  Tony Hunter,et al.  Structural basis for phosphoserine-proline recognition by group IV WW domains , 2000, Nature Structural Biology.

[28]  S. Muchmore,et al.  Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. , 2000, Molecular cell.

[29]  J. Noel,et al.  Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement , 2000, Nature Structural Biology.

[30]  W. Pratt,et al.  Stepwise Assembly of a Glucocorticoid Receptor·hsp90 Heterocomplex Resolves Two Sequential ATP-dependent Events Involving First hsp70 and Then hsp90 in Opening of the Steroid Binding Pocket* , 2000, The Journal of Biological Chemistry.

[31]  K. Lee,et al.  Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. , 1999, Biochemical pharmacology.

[32]  W. Kaelin,et al.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Morin,et al.  Functional requirement of p23 and Hsp90 in telomerase complexes. , 1999, Genes & development.

[34]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[35]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[36]  Neal Rosen,et al.  Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.

[37]  G. Mourier,et al.  On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules. , 1997, Molecular immunology.

[38]  J. Méry,et al.  The retro-inverso form of a homeobox-derived short peptide is rapidly internalised by cultured neurones: a new basis for an efficient intracellular delivery system. , 1995, Biochemical and biophysical research communications.

[39]  C. Swanton.  Cell-cycle targeted therapies. , 2004, The Lancet. Oncology.

[40]  C. Mantel,et al.  Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. , 2004, Blood.

[41]  D. Altieri.  Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.